OncoMatch

OncoMatch/Clinical Trials/NCT06976476

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Is NCT06976476 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies IgPro20 for multiple myeloma.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT06976476Data as of Sep 2026

Treatment: IgPro20The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

IgPro20

Cancer type

Multiple Myeloma

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

Must have received: bispecific antibody

Diagnosis of RRMM receiving a commercially available bispecific antibody

Cannot have received: CAR-T cell therapy

Planned CAR-T therapy in the next 6 months

Lab requirements

Blood counts

Neutrophils < 500 x 10^3 per mL, Platelets < 30 x 10^9 per mL [excluded]

Kidney function

Creatinine Cl <30 ml/min [excluded]

Neutrophils < 500 x 10^3 per mL, Platelets < 30 x 10^9 per mL; Creatinine Cl <30 ml/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity) · Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06976476 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify